Nell Kirchberger

Nell Kirchberger

Auto-generated profile, based on publicly available information

Nell Kirchberger

Oregon Health & Science University 2 Department of Cell, Developmental and Cancer Biology Portland, Oregon

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JLJason M. Link
Jason M. Link
JEJennifer R. Eng
Jennifer R. Eng
CPCarl Pelz
Carl Pelz
KMKevin MacPherson-Hawthorne
Kevin MacPherson-Hawthorne
PWPatrick J. Worth
Patrick J. Worth
RSRosalie C. Sears
Rosalie C. Sears
Patients with metastatic pancreatic ductal adenocarcinoma survive longer if disease spreads to the lung but not the liver. Here we generated overlapping, multi-omic datasets to identify molecular and cellular features that distinguish patients whose disease develops liver metastasis (liver cohort) from those whose disease develops lung metastasis without liver metastases (lung cohort). Lung cohort patients survived longer than liver cohort patients, despite sharing the same tumor subtype. We developed a primary organotropism (pORG) gene set enriched in liver cohort versus lung cohort primary tumors. We identified ongoing replication stress response pathways in high pORG/liver cohort tumors, whereas low pORG/lung cohort tumors had greater densities of lymphocytes and shared T cell clonal responses. Our study demonstrates that liver-avid pancreatic ductal adenocarcinoma is associated with tolerance to ongoing replication stress, limited tumor immunity and less-favorable outcomes, whereas low replication stress, lung-avid/liver-averse tumors are associated with active tumor immunity that may account for favorable outcomes.

21 February 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
KBKatie E. Blise
Katie E. Blise
SSShamilene Sivagnanam
Shamilene Sivagnanam
CBCourtney B. Betts
Courtney B. Betts
KBKonjit Betre
Konjit Betre
NKNell Kirchberger
Nell Kirchberger
KBKatelyn T. Byrne
Katelyn T. Byrne
Tumor molecular data sets are becoming increasingly complex, making it nearly impossible for humans alone to effectively analyze them. Here, we demonstrate the power of using machine learning (ML) to analyze a single-cell, spatial, and highly multiplexed proteomic data set from human pancreatic cancer and reveal underlying biological mechanisms that may contribute to clinical outcomes. We designed a multiplex immunohistochemistry antibody panel to compare T-cell functionality and spatial localization in resected tumors from treatment-naïve patients with localized pancreatic ductal adenocarcinoma (PDAC) with resected tumors from a second cohort of patients treated with neoadjuvant agonistic CD40 (anti-CD40) monoclonal antibody therapy. In total, nearly 2.5 million cells from 306 tissue regions collected from 29 patients across both cohorts were assayed, and over 1,000 tumor microenvironment (TME) features were quantified. We then trained ML models to accurately predict anti-CD40 treatment status and disease-free survival (DFS) following anti-CD40 therapy based on TME features. Through downstream interpretation of the ML models’ predictions, we found anti-CD40 therapy reduced canonical aspects of T-cell exhaustion within the TME, as compared with treatment-naïve TMEs. Using automated clustering approaches, we found improved DFS following anti-CD40 therapy correlated with an increased presence of CD44+CD4+ Th1 cells located specifically within cellular neighborhoods characterized by increased T-cell proliferation, antigen experience, and cytotoxicity in immune aggregates. Overall, our results demonstrate the utility of ML in molecular cancer immunology applications, highlight the impact of anti-CD40 therapy on T cells within the TME, and identify potential candidate biomarkers of DFS for anti-CD40–treated patients with PDAC.

3 July 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
RSRyan M. Shepard
Ryan M. Shepard
AGAnghesom Ghebremedhin
Anghesom Ghebremedhin
IPIsaraphorn Pratumchai
Isaraphorn Pratumchai
SRSally Robinson
Sally Robinson
CBCourtney Betts
Courtney Betts
JVJudith A. Varner
Judith A. Varner
Virulent infectious agents such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methicillin-resistant Staphylococcus aureus (MRSA) induce tissue damage that recruits neutrophils, monocyte, and macrophages, leading to T cell exhaustion, fibrosis, vascular leak, epithelial cell depletion, and fatal organ damage. Neutrophils, monocytes, and macrophages recruited to pathogen-infected lungs, including SARS-CoV-2–infected lungs, express phosphatidylinositol 3-kinase gamma (PI3Kγ), a signaling protein that coordinates both granulocyte and monocyte trafficking to diseased tissues and immune-suppressive, profibrotic transcription in myeloid cells. PI3Kγ deletion and inhibition with the clinical PI3Kγ inhibitor eganelisib promoted survival in models of infectious diseases, including SARS-CoV-2 and MRSA, by suppressing inflammation, vascular leak, organ damage, and cytokine storm. These results demonstrate essential roles for PI3Kγ in inflammatory lung disease and support the potential use of PI3Kγ inhibitors to suppress inflammation in severe infectious diseases.

27 May 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
APAmanda Poissonnier
Amanda Poissonnier
HRHope Rugo
Hope Rugo
WHWesley Horton
Wesley Horton
TKTina Kim
Tina Kim
ADAmy DeLuca
Amy DeLuca
LCLisa M. Coussens
Lisa M. Coussens
Purpose: Significant correlations exist between the presence of intratumoral macrophages, tumor progression, and poor outcomes in triple-negative breast cancer (TNBC) with limited therapeutic options available for advanced-stage disease. Preclinical studies revealed that inhibition of myelomonocytic colony-stimulating factor 1 (CSF1) or its receptor (CSF1R) plus cytotoxic chemotherapy decreased primary tumor growth kinetics and pulmonary metastases by CD8+ T cell–dependent mechanisms. This translational study evaluated CSF1R inhibition combined with eribulin in metastatic TNBC and explored rational preclinical combination strategies with PD-1/PD-L1 blockade based on clinical immune correlate analyses. Patients and Methods: A nonrandomized, open-label phase Ib/2 trial (NCT01596751) evaluated pexidartinib (PLX3397), a CSF1R inhibitor (CSF1Ri), plus eribulin mesylate in heavily pretreated individuals with metastatic TNBC. Clinical efficacy was assessed alongside peripheral blood correlates. Preclinical studies in transgenic mammary adenocarcinoma models examined biomarker-driven therapy combinations. Results: The 12-week progression-free survival rate was 36% (95% confidence interval, 22.2%–58.4%), with 44.8% of patients achieving clinical benefit; a subset experienced disease control beyond 6 months. Patients with partial response or stable disease demonstrated increased baseline leukocyte activation, including enrichment of CD8+ and CD4+ memory T cells and increased PD-1 expression on CD4+ T cells. In preclinical studies, CSF1Ri expanded the therapeutic index of PD-1 blockade, yielding transient tumor regression in ∼60% of mice and a transient expansion of effector and resident memory T cells. Conclusions: These clinical and preclinical findings provide rationale for therapies to increase the therapeutic index of αPD-1 therapy by diminishing the presence of T cell–suppressive myelomonocytic cells to improve outcomes for patients with refractory disease.

7 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
YGYifei Guo
Yifei Guo
JFJennifer M. Finan
Jennifer M. Finan
ABAlexandra Bartlett
Alexandra Bartlett
SSShamilene Sivagnanam
Shamilene Sivagnanam
KBKatie E. Blise
Katie E. Blise
RERobert Eil
Robert Eil
The tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is characterized by a limited infiltration of tumor-specific T cells and anti-tumor T cell activity. Extracellular factors in the PDAC TME have been widely reported to mediate immune suppression, but the contribution from tumor-intrinsic factors is not well understood. The RNA-binding protein, HuR ( ELAVL1 ), is enriched in PDAC and negatively correlates with T cell infiltration. In an immunocompetent Kras-p53-Cre (KPC) orthotopic model of PDAC, we found that genetic disruption of HuR impaired tumor growth due to a novel role of HuR inducing T-cell suppression. Importantly, we found that HuR depletion in tumors enhanced both T cell number and activation states and diminished myeloid phenotypes by comprehensive spatial profiling of the PDAC TME. Mechanistically, HuR mediated the stabilization of mTOR pathway transcripts, and inhibition of mTOR activity rescued the impaired function of local T cells. Translating these findings, we demonstrated that HuR depletion sensitized PDAC tumors to immune checkpoint blockade, while isogenic, wildtype tumors are resistant. For the first time, we show that HuR facilitates tumor immune suppression in PDAC by inhibiting T cell infiltration and function and implicate targeting HuR as a potential therapeutic strategy in combination with immunotherapy. SIGNIFICANCE: This study identified a novel mechanism that HuR supports pancreatic tumor growth by restricting T cell infiltration, promoting immune evasion. Our work supports targeting strategies against HuR in PDAC with the goal of enhancing PDAC sensitivity to immune-based cancer therapies, such as checkpoint blockade and T cell transfer.

2 May 2024
Verified
Other
Open access
PDF file
KBKatie E. Blise
Katie E. Blise
SSShamilene Sivagnanam
Shamilene Sivagnanam
CBCourtney B. Betts
Courtney B. Betts
KBKonjit Betre
Konjit Betre
NKNell Kirchberger
Nell Kirchberger
KBKatelyn T. Byrne
Katelyn T. Byrne
Supplementary Table S1. Statistical comparison between the Liudahl et al. original PDAC cohort and the selected subset used as Cohort 1 in this study. Mean value and standard error of the mean (SEM) shown for each variable. P-values computed using Fisher’s exact test for categorical variables, Wilcoxon rank-sum test for continuous variables, and log rank test for overall survival.